EMEA-001164-PIP01-11-M08 - paediatric investigation plan

vonicog alfa

Key facts

• Invented name:
  Veyvondi
• Active substance:
  vonicog alfa
• Therapeutic area:
  Congenital, familial and genetic disorders
• Decision number:
  P/0236/2024
• PIP number:
  EMEA-001164-PIP01-11-M08
• Pharmaceutical form(s):
  Powder and solvent for solution for injection
• Condition(s) / indication(s):
  Treatment of von Willebrand disease
• Route(s) of administration:
  Intravenous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  18/07/2024
• Compliance check done:
  Non

Decision

P/0236/2024: EMA decision of 18 July 2024 on the acceptance of a modification of an agreed paediatric investigation plan for vonicog alfa (Veyvondi), (EMEA-001164-PIP01-11-M08)

Adopted Reference Number: EMA/320605/2024